$307 Million is the total value of Opaleye Management Inc.'s 41 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| FULC | Exit | FULCRUM THERAPEUTICS INC | $0 | – | -143,600 | -100.0% | -0.11% | – |
| JNCE | Exit | JASPER | $0 | – | -669,944 | -100.0% | -0.22% | – |
| PRQR | Exit | PROQR THERAPEUTICS NV | $0 | – | -653,000 | -100.0% | -0.25% | – |
| BDTX | Exit | BLACK DIAMOND THERAPEUTICS | $0 | – | -275,000 | -100.0% | -0.33% | – |
| STRO | Exit | SUTRO BIOPHARMA INC | $0 | – | -307,000 | -100.0% | -0.34% | – |
| Exit | ASTRIA THERAPEUTICS INC | $0 | – | -305,000 | -100.0% | -0.61% | – | |
| STXS | Exit | SPECTRUM PHARMACEUTICALS | $0 | – | -3,074,995 | -100.0% | -0.71% | – |
| KPTI | Exit | KARYOPHARM THERAPEUTICS INC | $0 | – | -1,785,000 | -100.0% | -0.76% | – |
| EDAP | Exit | EDAP TMS S Asponsored adr | $0 | – | -380,000 | -100.0% | -0.84% | – |
| CYTK | Exit | CYTOKINETICS INC | $0 | – | -130,000 | -100.0% | -1.01% | – |
| NTLA | Exit | INTELLIA THERAPEUTICS INC | $0 | – | -120,000 | -100.0% | -1.17% | – |
| ACAD | Exit | ACADIA PHARMACEUTICALS INC | $0 | – | -217,000 | -100.0% | -1.24% | – |
| Exit | THESEUS PHARMACEUTICALS INC | $0 | – | -597,500 | -100.0% | -1.33% | – | |
| TBPH | Exit | THERAVANCE BIOPHARMA INC | $0 | – | -543,500 | -100.0% | -1.35% | – |
| CBAY | Exit | CYMABAY THERAPEUTICS INC | $0 | – | -566,700 | -100.0% | -1.48% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CODEXIS INC | 39 | Q3 2023 | 10.9% |
| CHIMERIX INC | 31 | Q3 2022 | 16.4% |
| XOMA CORP DEL | 27 | Q3 2023 | 3.6% |
| FIBROGEN INC | 26 | Q1 2021 | 6.8% |
| BIOLINERX LTD (Does not reflect a reverse stock split effectuated after June 30, 2019) | 26 | Q1 2020 | 2.4% |
| OCULAR THERAPEUTIX INC | 24 | Q3 2023 | 17.6% |
| AXOGEN INC | 20 | Q4 2019 | 18.7% |
| ETON PHARMACEUTICALS INC | 20 | Q3 2023 | 5.6% |
| AMARIN CORP PLC | 20 | Q4 2020 | 6.6% |
| IMPRIMIS PHARMACEUTICALS INC | 19 | Q1 2020 | 5.9% |
View Opaleye Management Inc.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| CHIMERIX INCSold out | February 13, 2023 | 0 | 0.0% |
| Larimar Therapeutics, Inc. | January 23, 2023 | 1,560,000 | 3.6% |
| TELA Bio, Inc. | June 10, 2022 | 1,557,500 | 10.7% |
| Gemini Therapeutics, Inc. /DESold out | February 01, 2022 | 0 | 0.0% |
| Adamas Pharmaceuticals IncSold out | January 26, 2022 | 0 | 0.0% |
| AVENUE THERAPEUTICS, INC. | February 12, 2021 | 9 | 11.0% |
| Cardiff Oncology, Inc. | February 12, 2021 | 9 | 11.0% |
| EDAP TMS SA | February 12, 2021 | 9 | 11.0% |
| Fortress Biotech, Inc. | February 12, 2021 | 9 | 11.0% |
| Gemini Therapeutics, Inc. /DE | February 12, 2021 | 9 | 11.0% |
View Opaleye Management Inc.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-25 |
| 4 | 2024-04-24 |
| 4 | 2024-04-19 |
| SC 13G/A | 2024-04-09 |
| SC 13G | 2024-04-08 |
| 4 | 2024-03-28 |
| 4 | 2024-03-22 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Opaleye Management Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.